The Role of the Complement Inhibitor CD59 on Breast Cancer Cells
Abstract
It is proposed that reversing the effects of CD59, a tumor cell expressed complement inhibitor, will allow effective immune-mediated clearance of tumor cells and improve prospects for successful immunotherapy. This study investigates the role of complement and CD59 in tumorigenesis. CD59 function is species selective, and we have determined that the expression of either rat or mouse CD59 on breast human breast cancer cells protects them from lysis by rat and mouse complement, respectively. We have determined species selectivity of human, rat and CD59, an important consideration for establishing human models of human cancer in rodents for the study of complement. We have further Identified the individual residues that confer human CD59 species selective activity. This data is an important step toward identifying the three dimensional structure of the CD59-C9 peptide ligand complex and may assist in design of CD59 inhibitors. Finally, we have established for the first time that CD59 expressed on the surface of a tumor cell can significantly promote tumor growth
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1999
- Accession Number
- ADA383176
Entities
People
- Stephen Tomlinson
Organizations
- NYU Langone Health